Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Contraceptive counseling and selection

Andrew M Kaunitz, MD
Section Editor
Robert L Barbieri, MD
Deputy Editor
Kristen Eckler, MD, FACOG


Contraception provides control over pregnancy timing and prevention of unintended pregnancy. In selecting a contraceptive method, individuals weigh factors such as efficacy, access, prevention of sexually transmitted infections, side effects, convenience, and noncontraceptive benefits. Contraceptive counseling provides education, dispels misinformation, facilitates selection of a method that will be successful for the individual, and encourages patient involvement in healthcare decisions and life goals. Discussing contraception brings the clinician and patient together to create a tailored care plan that meets the individual's reproductive needs over a lifetime.

This topic will review factors influencing contraceptive selection, guide the clinician through the selection process, review issues that impact compliance, and provide information on special populations. Information specific to each contraceptive method is presented in detail separately.

(See "Intrauterine contraception: Devices, candidates, and selection".)

(See "Etonogestrel contraceptive implant".)

(See "Depot medroxyprogesterone acetate for contraception".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 19, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Committee on Health Care for Underserved Women. Committee opinion no. 615: Access to contraception. Obstet Gynecol 2015; 125:250.
  2. Committee Opinion No. 654 Summary: Reproductive life planning to reduce unintended pregnancy. Obstet Gynecol 2016; 2:415.
  3. Oregon Foundation for Reproductive Health. "One Key Question" Initiative. 2012. http://www.onekeyquestion.org/ (Accessed on January 29, 2016).
  4. Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001-2008. Am J Public Health 2014; 104 Suppl 1:S43.
  5. Finer LB, Zolna MR. Declines in Unintended Pregnancy in the United States, 2008-2011. N Engl J Med 2016; 374:843.
  6. Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann 2010; 41:241.
  7. Healthy People 2020: Family Planning http://www.healthypeople.gov/2020/topics-objectives/topic/family-planning (Accessed on January 28, 2016).
  8. Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Effects of birth spacing on maternal health: a systematic review. Am J Obstet Gynecol 2007; 196:297.
  9. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.
  10. Jones RK, Kavanaugh ML. Changes in abortion rates between 2000 and 2008 and lifetime incidence of abortion. Obstet Gynecol 2011; 117:1358.
  11. Nettleman MD, Chung H, Brewer J, et al. Reasons for unprotected intercourse: analysis of the PRAMS survey. Contraception 2007; 75:361.
  12. Kost K, Singh S, Vaughan B, et al. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008; 77:10.
  13. Steiner MJ. Contraceptive effectiveness: what should the counseling message be? JAMA 1999; 282:1405.
  14. Lopez LM, Steiner M, Grimes DA, et al. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst Rev 2013; :CD006964.
  15. Trussell J, Hatcher RA, Cates W Jr, et al. A guide to interpreting contraceptive efficacy studies. Obstet Gynecol 1990; 76:558.
  16. Madden T, Secura GM, Nease RF, et al. The role of contraceptive attributes in women's contraceptive decision making. Am J Obstet Gynecol 2015; 213:46.e1.
  17. Trussel J. Choosing a contraceptive: efficacy, safety, and personal consideration.. In: Contraceptive Technology, 19, Hatcher RA, Trussell J, Nelson AL, et al. (Eds), Ardent Media, Inc., New York 2007. p.19.
  18. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118:184.
  19. Reeves MF, Zhao Q, Secura GM, Peipert JF. Risk of unintended pregnancy based on intended compared to actual contraceptive use. Am J Obstet Gynecol 2016; 215:71.e1.
  20. Hubacher D, Spector H, Monteith C, et al. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol 2016.
  21. ACOG strengthens LARC recommendations http://www.acog.org/About-ACOG/News-Room/News-Releases/2015/ACOG-Strengthens-LARC-Recommendations (Accessed on January 28, 2016).
  22. Committee on Gynecologic Practice Long-Acting Reversible Contraception Working Group. Committee Opinion No. 642: Increasing Access to Contraceptive Implants and Intrauterine Devices to Reduce Unintended Pregnancy. Obstet Gynecol 2015; 126:e44.
  23. National Institute for Health and Care Excellence. Contraception. Quality Standard (QS) 129. September 2016. https://www.nice.org.uk/guidance/qs129 (Accessed on September 19, 2016).
  24. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
  25. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998.
  26. Harper CC, Rocca CH, Thompson KM, et al. Reductions in pregnancy rates in the USA with long-acting reversible contraception: a cluster randomised trial. Lancet 2015; 386:562.
  27. Reducing unintended teen pregnancy in Colorado https://www.colorado.gov/pacific/sites/default/files/HPF_FP_UP-Reducing-Teen-Pregnancy.pdf (Accessed on July 06, 2015).
  28. Abraham M, Zhao Q, Peipert JF. Young Age, Nulliparity, and Continuation of Long-Acting Reversible Contraceptive Methods. Obstet Gynecol 2015; 126:823.
  29. Rocca CH, Thompson KM, Goodman S, et al. Funding policies and postabortion long-acting reversible contraception: results from a cluster randomized trial. Am J Obstet Gynecol 2016; 214:716.e1.
  30. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015; 12:e1001778.
  31. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011; 65:302.
  32. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th Edition, World Health Organization, 2015.
  33. Patel A, Schwarz EB, Society of Family Planning. Cancer and contraception. Release date May 2012. SFP Guideline #20121. Contraception 2012; 86:191.
  34. Dominick SA, McLean MR, Whitcomb BW, et al. Contraceptive Practices Among Female Cancer Survivors of Reproductive Age. Obstet Gynecol 2015; 126:498.
  35. Fouquier KF, Camune BD. Meeting the Reproductive Needs of Female Adolescents With Neurodevelopmental Disabilities. J Obstet Gynecol Neonatal Nurs 2015; 44:553.
  36. Committee on Ethics. ACOG Committee Opinion. Number 371. July 2007. Sterilization of women, including those with mental disabilities. Obstet Gynecol 2007; 110:217.
  37. Stewart FH, Harper CC, Ellertson CE, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA 2001; 285:2232.
  38. Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Physical examination prior to initiating hormonal contraception: a systematic review. Contraception 2013; 87:650.
  39. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
  40. Clinical Effectiveness Unit. Combined hormonal contraception. London (UK): Faculty of Sexual and Reproductive Healthcare; 2011 Oct. 28 http://guideline.gov/content.aspx?f=rss&id=36071 (Accessed on June 25, 2012).
  41. Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecol 1990; 76:552.
  42. Jellesen R, Strandberg-Larsen K, Jørgensen T, et al. Maternal use of oral contraceptives and risk of fetal death. Paediatr Perinat Epidemiol 2008; 22:334.
  43. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.
  44. Frost JJ, Darroch JE. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. Perspect Sex Reprod Health 2008; 40:94.
  45. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267.
  46. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995; 40:355.
  47. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90.
  48. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77:1.
  49. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.
  50. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000; 107:335.
  51. Birgisson NE, Zhao Q, Secura GM, et al. Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review. J Womens Health (Larchmt) 2015; 24:349.
  52. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117:1105.
  53. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010; 81:421.
  54. Thurman AR, Hammond N, Brown HE, Roddy ME. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? J Pediatr Adolesc Gynecol 2007; 20:61.
  55. Upson K, Reed SD, Prager SW, Schiff MA. Factors associated with contraceptive nonuse among US women ages 35-44 years at risk of unwanted pregnancy. Contraception 2010; 81:427.
  56. Weisman CS, Maccannon DS, Henderson JT, et al. Contraceptive counseling in managed care: preventing unintended pregnancy in adults. Womens Health Issues 2002; 12:79.
  57. Lee JK, Parisi SM, Akers AY, et al. The impact of contraceptive counseling in primary care on contraceptive use. J Gen Intern Med 2011; 26:731.
  58. Halpern V, Lopez LM, Grimes DA, et al. Strategies to improve adherence and acceptability of hormonal methods of contraception. Cochrane Database Syst Rev 2013; :CD004317.
  59. Gal N, Zite NB, Wallace LS. Evaluation of smartphone oral contraceptive reminder applications. Res Social Adm Pharm 2015; 11:584.
  60. Zapata LB, Tregear SJ, Tiller M, et al. Impact of Reminder Systems in Clinical Settings to Improve Family Planning Outcomes: A Systematic Review. Am J Prev Med 2015; 49:S57.
  61. Trent M, Thompson C, Tomaszewski K. Text Messaging Support for Urban Adolescents and Young Adults Using Injectable Contraception: Outcomes of the DepoText Pilot Trial. J Adolesc Health 2015; 57:100.
  62. Hou MY, Hurwitz S, Kavanagh E, et al. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial. Obstet Gynecol 2010; 116:633.
  63. Castaño PM, Bynum JY, Andrés R, et al. Effect of daily text messages on oral contraceptive continuation: a randomized controlled trial. Obstet Gynecol 2012; 119:14.
  64. Improving Contraceptive Use in the United States. Guttmacher Institute. 2008. https://www.guttmacher.org/pubs/2008/05/09/ImprovingContraceptiveUse.pdf (Accessed on March 03, 2016).
  65. Shelton JD, Angle MA, Jacobstein RA. Medical barriers to access to family planning. Lancet 1992; 340:1334.
  66. Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007; 109:1270.
  67. Foster DG, Parvataneni R, de Bocanegra HT, et al. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006; 108:1107.
  68. Foster DG, Hulett D, Bradsberry M, et al. Number of oral contraceptive pill packages dispensed and subsequent unintended pregnancies. Obstet Gynecol 2011; 117:566.
  69. Steenland MW, Rodriguez MI, Marchbanks PA, Curtis KM. How does the number of oral contraceptive pill packs dispensed or prescribed affect continuation and other measures of consistent and correct use? A systematic review. Contraception 2013; 87:605.
  70. Grindlay K, Grossman D. Prescription Birth Control Access Among U.S. Women at Risk of Unintended Pregnancy. J Womens Health (Larchmt) 2016; 25:249.
  71. Travasso C. App helps to improve contraception uptake in rural India. BMJ 2016; 352:i667.
  72. Siveregi A, Dudley L, Makumucha C, et al. Does counselling improve uptake of long-term and permanent contraceptive methods in a high HIV-prevalence setting? Afr J Prim Health Care Fam Med 2015; 7:779.
  73. Dermish A, Turok DK, Jacobson J, et al. Evaluation of an intervention designed to improve the management of difficult IUD insertions by advanced practice clinicians. Contraception 2016; 93:533.
  74. Thompson KM, Rocca CH, Kohn JE, et al. Public Funding for Contraception, Provider Training, and Use of Highly Effective Contraceptives: A Cluster Randomized Trial. Am J Public Health 2016; 106:541.
  75. Stevenson AJ, Flores-Vazquez IM, Allgeyer RL, et al. Effect of Removal of Planned Parenthood from the Texas Women's Health Program. N Engl J Med 2016; 374:853.